+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Devastating effects of chemotherapy: deafness and acute renal failure in a patient with epithelial ovarian cancer



Devastating effects of chemotherapy: deafness and acute renal failure in a patient with epithelial ovarian cancer



International Journal of Gynecological Cancer 16(Suppl. 1): 394-396



Paclitaxel and platinum combination is the standard chemotherapy regimen for patients with advanced epithelial ovarian cancer. The dose-limiting toxicity effects of this combination are myelosuppression and neuropathy. Herein, we report a case of a 71-year-old female with advanced epithelial ovarian cancer who developed bilateral total loss of hearing and acute renal failure related with paclitaxel- and carboplatin-based chemotherapy. Acute renal failure accompanied by complete loss of hearing in patients treated with carboplatin and paclitaxel combination has not been previously reported. This uncommon adverse effect of carboplatin and paclitaxel combination was discussed, and all the literature in English related with the toxicity of paclitaxel and carboplatin were reviewed.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 048756560

Download citation: RISBibTeXText

PMID: 16515631

DOI: 10.1111/j.1525-1438.2006.00214.x


Related references

Successful management of chemotherapy in a stage IV ovarian cancer patient with chronic renal failure. International Cancer Conference Journal 1(4): 230-234, 2012

Acute renal failure associated with intraperitoneal cisplatin chemotherapy with systemic thiosulfate protection in ovarian cancer patients. European Journal of Gynaecological Oncology 12(5): 403-406, 1991

A case report of acute renal failure induced by melphalan in a patient with ovarian cancer. Gan no Rinsho. Japan Journal of Cancer Clinics 34(14): 2015-2018, 1988

Histopathologic assessment of chemotherapy effects in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking. Gynecologic Oncology 106(1): 160-163, 2007

Acute renal failure. Managing a devastating illness. Postgraduate Medicine 82(4): 96-105, 1987

Treating relapsed epithelial ovarian cancer with luteinizing hormone-releasing agonist (goserelin) after failure of chemotherapy. Israel Medical Association Journal 4(8): 597-599, 2002

Cyclophosphamide "metronomic" chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer. Bmc Cancer 7: 65, 2007

Pharmacokinetics of combination chemotherapy with paclitaxel and carboplatin in a patient with advanced epithelial ovarian cancer undergoing hemodialysis. Oncology Letters 1(3): 511-513, 2010

A matched control study of familial epithelial ovarian cancer: patient characteristics, response to chemotherapy and outcome. Annals of Oncology 6(1): 80-82, 1995

Successful high-dose methotrexate chemotherapy in a patient with acute lymphocytic leukemia who developed acute renal failure during the initial treatment. Pediatrics International 49(6): 1018-1019, 2007

Management of advanced ovarian epithelial cancer in the renal transplant patient. Gynecologic Oncology 50(3): 374-378, 1993

Massive left atrial calcification and devastating systemic emboli in a patient with chronic renal failure. American Journal of Kidney Diseases 40(2): 416-419, 2002

Acute leukemia following cisplatin-based chemotherapy in a patient with ovarian cancer. Journal of the National Cancer Institute 82(5): 431-432, 1990

Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes. International Journal of Gynecological Cancer 22(2): 232-237, 2012

Secondary acute nonlymphocytic leukemia following successful chemotherapy combining cisplatin, doxorubicin, and cyclophosphamide for stage IV epithelial ovarian cancer. Archives of Gynecology and Obstetrics 263(4): 206-207, 2000